COMP <GO>
USNA vs MRK // EV/EBITDA & P/E VALUATION
USANA Health Sciences Inc. (NYSE) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: USNA 3
— MRK 9
▲ EV/EBITDA & P/E VALUATION LEADER: USNA
LAST: $14.34 (-1.91%) • MKT CAP: $265.0M
valuation
2.7x
LAST: $146.33 (+3.83%) • MKT CAP: $361.02B
valuation
15.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (USNA VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | USNA | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 78.30% | 74.80% | +3.50 | USNA | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 7.90% | 20.70% | -12.80 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 2.7x | 15.3x | -12.60 | USNA | /valuation <GO> |
| Free Cash Flow Yield | 3.22% | 3.42% | -0.20 | MRK | /fcf-yield <GO> |
| Operating Margin | 4.00% | 34.30% | -30.30 | MRK | /operating-margins <GO> |
| Net Profit Margin | 1.20% | 28.10% | -26.90 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 8.30% | 1.30% | +7.00 | USNA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.56 | 5.19 | -1.63 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.8 | 51.7 | -5.90 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 22.9x | 18.4x | +4.50 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $265.0M | $361.02B | -$360.76B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | USNA REV | MRK REV | USNA GROSS % | MRK GROSS % | USNA FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $925.3M | $65.01B | 78.3% | 74.8% | $8.5M | $12.36B |
| FY 2024 | $854.5M | $64.17B | 81.1% | 76.3% | $50.9M | $18.10B |
| FY 2023 | $921.0M | $60.12B | — | — | $70.6M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
USNA // BETA —
MRK // BETA 0.92